George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008;455(7215):975-8. doi:10.1038/nature07397
van Ham TJ, Kokel D, Peterson RT. Apoptotic cells are cleared by directional migration and elmo1- dependent macrophage engulfment. Curr Biol. 2012;22(9):830-6. doi:10.1016/j.cub.2012.03.027
Wei G, Margolin AA, Haery L, et al. Chemical genomics identifies small-molecule MCL1 repressors and BCL-xL as a predictor of MCL1 dependency. Cancer Cell. 2012;21(4):547-62. doi:10.1016/j.ccr.2012.02.028
Brown-Endres L, Schoenfeld D, Tian F, et al. Expression of the p53 target CDIP correlates with sensitivity to TNFα-induced apoptosis in cancer cells. Cancer Res. 2012;72(9):2373-82. doi:10.1158/0008-5472.CAN-11-3369
Huillard E, Hashizume R, Phillips JJ, et al. Cooperative interactions of BRAFV600E kinase and CDKN2A locus deficiency in pediatric malignant astrocytoma as a basis for rational therapy. Proc Natl Acad Sci U S A. 2012;109(22):8710-5. doi:10.1073/pnas.1117255109
Chou DHC, Holson EB, Wagner FF, et al. Inhibition of histone deacetylase 3 protects beta cells from cytokine-induced apoptosis. Chem Biol. 2012;19(6):669-73. doi:10.1016/j.chembiol.2012.05.010
Adams DJ, Dai M, Pellegrino G, et al. Synthesis, cellular evaluation, and mechanism of action of piperlongumine analogs. Proc Natl Acad Sci U S A. 2012;109(38):15115-20. doi:10.1073/pnas.1212802109
Puissant A, Frumm SM, Alexe G, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition. Cancer Discov. 2013;3(3):308-23. doi:10.1158/2159-8290.CD-12-0418
Crompton BD, Carlton AL, Thorner AR, et al. High-throughput tyrosine kinase activity profiling identifies FAK as a candidate therapeutic target in Ewing sarcoma. Cancer Res. 2013;73(9):2873-83. doi:10.1158/0008-5472.CAN-12-1944
Okada Y, Plenge RM. Editorial: entering the age of whole-exome sequencing in rheumatic diseases: novel insights into disease pathogenicity. Arthritis Rheum. 2013;65(8):1975-9. doi:10.1002/art.38011